Analysts Bet On Specialty Portfolio Ramp-Up And Cost Moderation


Analysts expect Sun Pharmaceutical Industries Ltd.’s expansion of its specialty portfolio, robust franchise building in branded generics, new drug applications in the U.S. generics market, and cost controls to aid growth.

Net profit of India’s largest drugmaker rose 11% year-on-year to Rs 2,262 crore for the quarter ended September, according to its exchange filing. That compares with the Rs 1,965-crore consensus estimate of analysts tracked by Bloomberg.

Sun Pharma Q2 Results FY23: Key Highlights (YoY)

  • Revenue up 14% to Rs 10,952 crore

  • Ebitda up 18% at Rs 3,198 crore

  • Margin at 29.2% versus 28.1%

Shares of Sun Pharma were trading 0.23% lower at open on Wednesday, while the benchmark Nifty 50 eased 0.16% on the NSE. Of the 44 analysts tracking the company, 41 have a ‘buy’ rating, two suggest a ‘hold, and one recommends a ‘sell’, according to Bloomberg data. The 12-month consensus price target implies an upside of 7.3%.

Brokerages’ take on Sun Pharma’s quarterly results:


Source link

What is your reaction?

In Love
Not Sure

You may also like

Comments are closed.

More in:Business